Medivir CMO moving over to Modus Therapeutics

Swedish biotech firm Karolinska Development's (STO: KDEV) portfolio company Modus Therapeutics, which is focused on sickle cell disease (SCD) and malaria, announces that Dr John Öhd has been appointed to a position as chief medical officer (CMO).

At present, Dr Öhd is working at fellow Stockholm-based biotech Medivir (OMX: MVIR) as CMO and a member of the company`s executive management team. Before his current position, he was Medivir's director of clinical R&D. Prior to joining Medivir, Dr Öhd was senior director of experimental medicine at Shire based in Nyon, Switzerland. Between 2007 and 2012, Dr Öhd held several positions of increasing responsibility at AstraZeneca in Södertälje, Sweden.

"We are delighted that we have been able to attract Dr Öhd as our new CMO. John not only has extensive clinical development experience, but he brings to Modus important prior experience working on SCD at Shire. I am confident that he will make important contributions to Modus as we progress the clinical development of sevuparin for SCD," states Ellen Donnelly, chief executive of Modus Therapeutics.